CalciMedica, Inc. Common Stock (CALC) - Cash Flow Conversion Efficiency
Based on the latest financial reports, CalciMedica, Inc. Common Stock (CALC) has a cash flow conversion efficiency ratio of 0.731x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.85 Million) by net assets ($-6.64 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
CalciMedica, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2018–2025)
This chart illustrates how CalciMedica, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read CalciMedica, Inc. Common Stock (CALC) financial obligations for a breakdown of total debt and financial obligations.
CalciMedica, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of CalciMedica, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Baselode Energy Corp
V:FIND
|
-0.665x |
|
SINTX Technologies Inc
NASDAQ:SINT
|
-0.619x |
|
Auriginal Mining Corp.
V:AUME
|
-0.021x |
|
USWE Sports AB
ST:USWE
|
-0.007x |
|
WALLBOX N.V. CL.A EO-12
F:67E
|
N/A |
|
SOS Limited
NYSE:SOS
|
-276.877x |
|
Tay Ninh Cable Car Tour Co.
VN:TCT
|
0.005x |
|
Harper Hygienics S.A.
WAR:HRP
|
-0.021x |
Annual Cash Flow Conversion Efficiency for CalciMedica, Inc. Common Stock (2018–2025)
The table below shows the annual cash flow conversion efficiency of CalciMedica, Inc. Common Stock from 2018 to 2025. For the full company profile with market capitalisation and key ratios, see CalciMedica, Inc. Common Stock (CALC) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-6.64 Million | $-21.18 Million | 3.189x | +317.31% |
| 2024-12-31 | $14.41 Million | $-21.15 Million | -1.467x | +53.48% |
| 2023-12-31 | $8.16 Million | $-25.73 Million | -3.154x | -347.72% |
| 2022-12-31 | $-9.23 Million | $-11.76 Million | 1.273x | +362.85% |
| 2021-12-31 | $65.02 Million | $-31.50 Million | -0.484x | -43.21% |
| 2020-12-31 | $94.79 Million | $-32.06 Million | -0.338x | +69.21% |
| 2019-12-31 | $28.41 Million | $-31.21 Million | -1.099x | +53.20% |
| 2018-12-31 | $12.02 Million | $-28.22 Million | -2.348x | -- |
About CalciMedica, Inc. Common Stock
CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated calcium (CRAC) channel inhibitors for the treatment of acute pancreatitis, asparaginase-… Read more